Thomas W. Comollo

Thomas W. Comollo

Auto-generated profile, based on publicly available information

Thomas W. Comollo

Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKStanley G. Kimani
Stanley G. Kimani
SKSushil Kumar
Sushil Kumar
NBNitu Bansal
Nitu Bansal
KSKamalendra Singh
Kamalendra Singh
VKVladyslav Kholodovych
Vladyslav Kholodovych
RBRaymond Birge
Raymond Birge
TAM receptors (Tyro-3, Axl, and Mertk) are a family of three homologous type I receptor tyrosine kinases that are implicated in several human malignancies. Overexpression of TAMs and their major ligand Growth arrest-specific factor 6 (Gas6) is associated with more aggressive staging of cancers, poorer predicted patient survival, acquired drug resistance and metastasis. Here we describe small molecule inhibitors (RU-301 and RU-302) that target the extracellular domain of Axl at the interface of the Ig-1 ectodomain of Axl and the Lg-1 of Gas6. These inhibitors effectively block Gas6-inducible Axl receptor activation with low micromolar IC50s in cell-based reporter assays, inhibit Gas6-inducible motility in Axl-expressing cell lines, and suppress H1299 lung cancer tumor growth in a mouse xenograft NOD-SCIDγ model. Furthermore, using homology models and biochemical verifications, we show that RU301 and 302 also inhibit Gas6 inducible activation of Mertk and Tyro3 suggesting they can act as pan-TAM inhibitors that block the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. Together, these observations establish that small molecules that bind to the interface between TAM Ig1 domain and Gas6 Lg1 domain can inhibit TAM activation, and support the further development of small molecule Gas6-TAM interaction inhibitors as a novel class of cancer therapeutics.

30 August 2019
Verified
Book Chapter
Closed access
PDF file
TCThomas W. Comollo
Thomas W. Comollo
CZChuangeng Zhang
Chuangeng Zhang
XZXinle Zou
Xinle Zou
RKRobert S. Kass
Robert S. Kass


29 July 2011 in Biochemistry
Verified
Journal Article
Closed access
NPNootan Pandey
Nootan Pandey
CMChaturbhuj A. Mishra
Chaturbhuj A. Mishra
DMDinesh Manvar
Dinesh Manvar
AUAlok K. Upadhyay
Alok K. Upadhyay
TTTanaji T. Talele
Tanaji T. Talele
VPVirendra N. Pandey
Virendra N. Pandey